Discover why a one-time gene-editing cholesterol therapy could transform heart disease prevention

The interim Phase I trial data was only from 35 people, but results look good so far.

The interim Phase I trial data was only from 35 people, but results look good so far.

If it continues to work in further studies, a gene therapy in development could eliminate the need for daily pills or regular injections.

Discover why a one-time gene-editing cholesterol therapy could transform heart disease prevention